Technology evaluation: lerdelimumab, Cambridge Antibody Technology.
Cambridge Antibody Technology is developing lerdelimumab (CAT-152), the lead in a series of human anti-TGF beta 2 antibodies, for its potential in preventing post-operative scarring in patients undergoing surgery for glaucoma (trabulectomy). It also has potential for the treatment of fibrosis, cataract, retinopathy and connective tissue disease.
Cordeiro
M Francesca
MF
Department of Pathology & Department of Glaucoma, Institute of Ophthalmology and Moorfields Eye Hospital, Bath Street, London, EC1V 9EL, UK. m.cordeiro@ucl.ac.uk
D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D002921:Cicatrix / Q000517:prevention & control; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors*; D053781:Transforming Growth Factor beta2
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C509041:TGFB2 protein, human; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2; C475848:Lerdelimumab